PhotoPharmics Gets FDA Breakthrough Status for Parkinson’s PhotoTherapy
May 1, 2020
PhotoPharmics, a pioneer in specialized phototherapy, announced on April 29, that it has received FDA Breakthrough device designation for the company’s non-invasive Specialized Phototherapy Device.
“Hats off to Utah’s PhotoPharmics,” said Kelvyn Cullimore, president and CEO of BioUtah. “Earning this Breakthrough designation is a significant value driver for a privately-owned device company.”
“Our device is the first specialized phototherapy device to achieve this status,” said Kent Savage, CEO of PhotoPharmics. “Our focus is to help people with Parkinson’s improve function… we think this recognition by FDA validates our work.”
The prescription phototherapy for Parkinson’s patients is intended to be used an adjunct treatment with standard dopaminergic therapy and is designed primarily for home use.
Recent News
- Canyon Labs Launches Expanded Reprocessing Validation Services for Medical Devices
- Connecting with Life Sciences in Logan
- Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Ratio Therapeutics Enters into Research Collaboration, License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
- Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
- Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
